ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have entered
into an alliance for developing and marketing Medarex's MDX-210
Bispecific product. Medarex will be primarily responsible for
development through phase II trials, and Ciba will be responsible
for phase III trials, regulatory approvals, and commercial launch.
MDX-210 is designed to induce tumor cell killing by simultaneously
binding to the HER-2 protein on the cancer cell surface and to
a key receptor on immune system killer cells. The product is currently
in clinical trials for the treatment of breast, ovarian, prostate,
and other tumors.